Autologous platelet-rich plasma to improve reproductive outcomes in women with diminished ovarian reserves: a prospective pilot study
Journal of Clinical and Experimental Reproductive Medicine · 13.03.2026 · 1 (3) · 1
DOI: 10.46439/reproductivemed.3.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Reproductive Medicine, online erschienen am 13.03.2026. Verfasst von Michelle Jia Min Loh und 11 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
To investigate if intraovarian autologous platelet-rich plasma (PRP) infusion improve ovarian reserve markers and fertility outcomes in women with diminished ovarian reserve (DOR).
Methods
A single-arm, prospective intervention study was conducted between July 2023 and April 2024. Women aged 21–40 years with DOR and previous poor response to maximal ovarian stimulation during IVF were recruited. Anti-mullerian hormone (AMH) and antral follicle count (AFC) were measured on menstrual cycle days 2–3, followed by PRP injection on days 5–15. AMH and AFC were reassessed 2–3 months later, and ovarian stimulation commenced 3–6 months post PRP. Primary outcomes were changes in ovarian reserve markers and fertility outcomes. Secondary outcomes were clinical pregnancy and live birth rates.
Results
Thirteen women underwent PRP injection (median age: 38.0 years; median body mass index: 22.2 kg/m2). Median AMH and AFC showed a numerical increase post-PRP (0.17 to 0.26 ng/ml and 5.0 to 6.0 respectively), though these changes did not reach statistical significance (p=0.695 and p=0.509). Median number oocytes retrieved increased (1.8 to 3.0 (p=0.099)). Median number of mature oocytes retrieved increased significantly (2.0 to 3.0; p=0.019) and embryos created (1.0 to 2.0; p=0.025). Clinical pregnancy rate was 41.7% and live birth rate was 33.3%. No complications were reported during PRP infusion.
Conclusion
Intraovarian PRP is a safe treatment option which may improve reproductive outcomes in DOR women. Larger, well-controlled studies to establish clinical applicability are warranted.
Zitieren
APA
Loh, M. J. M., Fan, Y., Loy, S. L., Wong, K. Y., Ku, C. W., Ee, T. X., Tan, T. Y., Viardot-Foucault, V., Liu, S., Nadarajah, S., Loh, S. F., & Chan, J. K. Y. (2026). Autologous platelet-rich plasma to improve reproductive outcomes in women with diminished ovarian reserves: a prospective pilot study. Journal of Clinical and Experimental Reproductive Medicine, 1(3), 1. https://doi.org/10.46439/reproductivemed.3.010
Vancouver
Loh MJM, Fan Y, Loy SL, Wong KY, Ku CW, Ee TX, et al. Autologous platelet-rich plasma to improve reproductive outcomes in women with diminished ovarian reserves: a prospective pilot study. Journal of Clinical and Experimental Reproductive Medicine. 2026;1(3):1. doi:10.46439/reproductivemed.3.010
BibTeX
@article{Loh2026,
author = {Loh, Michelle Jia Min and Fan, Yiping and Loy, See Ling and Wong, Ker Yi and Ku, Chee Wai and Ee, Tat Xin and Tan, Tse Yeun and Viardot-Foucault, Veronique and Liu, Shuling and Nadarajah, Sadhana and Loh, Seong Feei and Chan, Jerry Kok Yen},
title = {Autologous platelet-rich plasma to improve reproductive outcomes in women with diminished ovarian reserves: a prospective pilot study},
journal = {Journal of Clinical and Experimental Reproductive Medicine},
year = {2026},
volume = {1},
number = {3},
pages = {1},
doi = {10.46439/reproductivemed.3.010}
}
EUVIMED